There was a mention of being open to acquisition if it is in the best interests if the company.
DW alluded to big names that can't yet be mentioned until a formal release of the full paper by Toby in a few weeks. That will be very interesting as the new potential silo would bring PNV into the orbit of some significant players in the cell treatment space. Novo Nordisk is used as an example but they are relative newcomers.
Key players include Novartis, Gilead Sciences/Kite Pharma, Bristol-Myers Squibb, Allogene Therapeutics, and CRISPR Therapeutics
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.24 |
Change
0.025(2.06%) |
Mkt cap ! $853.1M | |||
| Open | High | Low | Value | Volume |
| $1.22 | $1.24 | $1.21 | $695.7K | 568.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 18 | 10101 | $1.24 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.25 | 12390 | 14 |
View Market Depth
| Last trade - 12.15pm 17/06/2025 (20 minute delay) ? |
| PNV (ASX) Chart |